

26th July 2021

To
Department of Corporate Services, **BSE-Limited**PJ Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: **BSE - 524500** 

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No C-1, G Block,
BKC, Bandra (E)- Mumbai 400 051
Scrip Code: NSE - KILITCH

Dear Sir/ Madam,

## Sub: Kilitch Drugs (India) Limited - Press Release

Please find enclosed Press Release titled "Kilitch Drugs starts production of Cephalosporins Injectables at Ethiopia Plant" dated 26<sup>th</sup> July 2021.

The above is for information and dissemination to the public at large.

Thanking you

Yours faithfully

For Kilitch Drugs (India) Limited

**Mukund Mehta** 

Director

DIN: 00147876











## Kilitch Drugs starts production of Cephalosporin Injectables at Ethiopia Plant

**Mumbai July 26, 2021**, Kilitch Drugs India Ltd. Leading manufacturer of Injectables in India starts production of the Cephalosporin Injectables at Ethiopia manufacturing plant. The Company had started its greenfield project in Ethiopia in 2018 to build a world-class Injectable plant.

In early 2021 the company has started production of Antiseptic and Disinfectant products to help Ethiopia fight against the COVID-19 pandemic.

For Cephalosporin Injectables plant is having total capacity of 26.4 million vials yearly while Ethiopia is having a demand for 16 million Vials. Through this plant most of the capacity is going to be sold in Ethiopia through Government & other institutes.

Commenting on this Mr. Mukund Mehta, Chairman & Managing Director of Kilitch Drugs said "Africa always has been our focus market for our products. We have started this manufacturing plant to cater to the African markets directly as there very few injectable manufacturing plants in whole continentand in turn help the people of Africa. Also, there is more demand than supply in the Ethiopia so we see that this has good business opportunity."



## About Kilitch Drugs (India) Limited:

Established in 1978, Kilitch Drug (India) is a successful pharmaceutical solution company. Company has major focus in African region and have strong foothold across key African countries with 350 products in 26 African countries.

The Company has manufacturing plant located in Mumbai with a dedicated dry powder section and small volume liquid ampoules and vial. The Company's manufacturing plants are certified by WHO GMP, ISO 9001, ISO 13845, PPB Kenya, NAFDAC Nigeria, FDA Ghana, MOH Sudan etc.

The Company's strong clientele includes Intas, Indoco Remedies, Mankind Pharma, Shalina Laboratories to name among few.

For FY21 the Company has achieved Total Revenue of Rs. 74.21 crores with PAT of Rs. 6.16 crores.

For further information please contact corporate communication advisor:

Kirin Advisors

Sunil Mudgal - Director sunil@kirinadvisors.com
M - 9869275849